Friday, February 8, 2013

SUGGESTION OF TREATMENT OPTIONS IN PATIENTS WITH ACTIVATED B CELL LYMPHOMA AFTER FAILURE OF R-CHOP IF PATIENT IS A POOR CANDIDATE

IN Not transplant candidates:
The options are:

1.Revlimid+ Rituxan
2.Rev+RICE is being trial
3.Reduced Conditioning Allogeneic Transplant
4.R+Bendamustine
5.Whyndam  R-EPOCH,
6.Velcade + Chemotherapy in the ABC subtype

Nn CNS prophylaxis, with addition of RITUXAN,  the  incidence of CNs relapse has decreased.
Large Cell lymphoma with Bone Marrow infiltration in 50% of case it is because of small cell component is actually infiltrating which does impact the  prognosis considerably.  So, NO CNS prophylaxis supported.
-------------------------------------------------------------------------------------------------------
TREATMENT OPTIONS IN MANTLE CELL (SOX 11 MARKS AN INDOLENT COURSE)

1.R-HYPERCVAD (MODIFIED)
2.R-BENDAMUSTINE
3. 4 CYCLES OF R-DHAP (LYMA TRIAL), COULD BE  FOLLOWED BY REVELIMD OR RITUXAN MAINTENANCE
4.HIGH DOSE ARA-C CONTAINING REGIMEN
5 R-CHOP ALTERNATING WITH R-DHAP
6. IBRUTINIB
--------------------------------------------------------------------------------------------------

CLL, TREATMENT OPTION

1.RITUXAN-BENDAMUSTINE
2.FLUDARABINE, CYTOXAN, RITUXAN (FCR)
3.FOR AUTOIMMUNE HEMOLYTIC ANEMIA- PREDNISONE, IV IG , RITUXAN COMBINATION PRIOR TO STARTING THERAPY.
4. IBRUTINIB
5. LOW INTENSITY ALLO TRANSPLANT




CONTINUING MEDICAL EDUCATION CERTIFICATE


certifies that
Mutombo Kankonde, MD
2400 Trawood Drive
Suite 303
El Paso, TX 79936
has participated in the enduring material titled

Tailored Hematology: Challenging Community Cases in Non-Hodgkin Lymphoma

February 8, 2013
and is awarded 0.50  AMA PRA Category 1 Credit(s)™.
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.
Certificate Number: 41862411 Cyndi Grimes
Cyndi Grimes
Director, Continuing Medical Education
Medscape, LLC




No comments: